

Mori K, Ueda Y, <u>Ariumi Y</u> , Dansako H, Ikeda M, Kato N.	Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.	Virus Genes	In press		2012
Osugi K, Suzuki H, Nomura T, <u>Ariumi Y</u> , Shibata H, Maki M.	Identification of the P-body components PATL1 as a novel ALG2-interacting protein by in silico and Far-Western screening of proline-rich proteins.	J Biochem	In press		2012
Murayama A, Weng L, Date T, Akazawa D, Tian X, Suzuki T, <u>Kato T</u> , Tanaka Y, Mizokami M, Wakita T, Toyoda T.	RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells.	PLoS Pathog	6	e1000885	2010
Takahashi H, Akazawa D, <u>Kato T</u> , Date T, Shirakura M, Nakamura N, Mochizuki H, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Suzuki T, Wakita T.	Biological properties of purified recombinant HCV particles with an epitope-tagged envelope.	Biochem Biophys Res Commun	395	565-571	2010
Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, <u>Kato T</u> , Matsuura Y, Watanabe H, Wakita T, Suzuki T.	Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles.	J Biol Chem	286	37264-37273	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K,	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis.	Hepatology	54	425-433	2011

Liang TJ, Wakita T, Kato T.					
Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S, Yokosuka O, Watanabe H, Wakita T, Kato T.	Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2.	Biochem Biophys Res Commun	410	404-409	2011
Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Tsuchiya K, Kato T, Wakita T, Watanabe M.	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture.	Hepatol Res	41	258-269	2011
Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, Tanaka Y, Mizokami M, Yokosuka O, Nomoto A, Wakita T.	Production of infectious chimeric hepatitis C Virus Genotype 2b Harboring Minimal Regions of JFH-1.	J Virol	86(4)	2143-2152	2012
Moriya K, Miyoshi H, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Yotsuyanagi H, Moriishi K, Matsuura Y, Suzuki T, Miyamura T, Koike K.	Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: Analysis using mouse model and cultured cells.	Am J Pathol	175	1515-1524	2009
Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie H, Shintani Y, Yotsuyanagi H, Miyamura T, Suzuki T, Koike K.	Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperone, prohibitin, in cells expressing hepatitis C virus core protein.	Hepatology	50	378-386	2009

Yotsuyanagi H, Kikuchi Y, Tsukada K, Nishida K, Kato M, Sakai H, Takamatsu J, Hige S, Chayama K, Moriya K, <u>Koike K</u> .	Chronic hepatitis C in patients coinfectd with human immunodeficiency virus in Japan: a retrospective multicenter analysis.	Hepatol Res	39	657-663	2009
Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Fujisawa J, Seki T, <u>Koike K</u> , Okazaki K.	Hepatitis B virus X protein shifts hepatic Smad3-mediated signaling from tumor-suppression to oncogenesis in chronic hepatitis B.	Hepatology	49	1203-1217	2009
Yanagimoto S, Tatsuno K, Okugawa S, Kitazawa T, Tsukada K, <u>Koike K</u> , Kodama T, Kimura S, Shibasaki Y, Ota Y.	A single amino acid of toll-like receptor 4 that is pivotal for its signaltransduction and subcellular localization.	J Biol Chem	284	3513-3520	2009
Ishizaka N, Ishizaka Y, Yamakado M, Toda E, <u>Koike K</u> , Nagai R.	Association between metabolic syndrome and carotid atherosclerosis in individuals without diabetes based on the oral glucose tolerance test.	Atherosclerosis	204 (2)	619-623	2009
<u>Koike K</u> .	Steatosis, Liver injury and hepatocarcinogenesis in hepatitis C viral infection.	J Gastroenterol	44 Suppl	82-88	2009
Ichibangase T, Moriya K, <u>Koike K</u> , Imai K.	Limitation of immunoaffinity column for the removal of abundant proteins from plasma in quantitative plasma proteomics.	Biomed Chromatogr	23	480-487	2009
<u>Koike K</u> , Tsutsumi T, Yotsuyanagi H, Moriya K.	Lipid metabolism and liver disease in hepatitis C viral infection.	Oncology	78 Suppl 1	24-30	2010
Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R,	Thrombocytopenia is more severe in patients with	J Gastroenterol	45	876-884	2010

Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki A, Koike Y, Yatomi Y, Omata M, <u>Koike K.</u>	advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.				
Ishizaka N, Ishizaka Y, Toda E, Yamakado M, <u>Koike K.</u> , Nagai R.	Association between gamma-glutamyltransferase levels and insulin resistance according to alcohol consumption and number of cigarettes smoked.	J Atheroscler Thromb	17	476-485	2010
Ohtomo N, Tomiya T, Tanoue Y, Inoue Y, Nishikawa T, Ikeda H, Seyama Y, Kokudo N, Shibahara J, Fukayama M, <u>Koike K.</u> , Shirataki H, Fujiwara K.	Expression of alpha-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor.	Int J Oncol	37	1417-1423	2010
Ikeda H, Ohkawa R, Watanabe N, Nakamura K, Kume Y, Nakagawa H, Yoshida H, Okubo S, Yokota H, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, <u>Koike K.</u> , Yatomi Y.	Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C.	Clin Chim Acta	411	765-770	2010
Okuse C, Yotsuyanagi H, Yamada N, Okamoto M, Ikeda H, Kobayashi M, Fukuda Y, Takahashi H, Nagase Y, Suzuki Y, Matsunaga K, Ishii T, Matsumoto N, <u>Koike K.</u> , Suzuki M, Itoh F.	Effect of nucleoside analogue-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B.	Hepatol Res	40	461-469	2010

Kanamori H, Yuhashi K, Ohnishi S, <u>Koike K</u> , Kodama T.	RNA-dependent RNA polymerase of hepatitis C virus binds to its coding region RNA stem-loop structure, 5BSL3.2, and its negative strand.	J Gen Virol	91	1207-1212	2010
Moriya K, Miyoshi H, Shinzawa S, Tsutsumi T, Fujie H, Goto K, Shintani Y, Yotsuyanagi H, <u>Koike K</u> .	Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells.	J Med Virol	82	776-792	2010
Molina-Jiménez F, Benedicto I, Murata M, Martín-Villalobos S, Seki T, Pintor-Toro J, Tortolero M, Moreno-Otero R, Okazaki K, <u>Koike K</u> , Barbero J, Matsuzaki K, Majano P, López- Cabrera M	Expression of pituitary tumor transforming gene 1 (PTTG1)/securin in hepatitis B virus-associated liver diseases: Evidence for a hepatitis B virus X protein-mediated inhibition of PTTG1 ubiquitination and degradation.	Hepatology	51	777-787	2010
Hmwe SS, Aizaki H, Date T, Murakami K, Ishii K, Miyamura T, <u>Koike K</u> , Wakita T, Suzuki T	Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.	Antiviral Res.	85	520-524	2010
Watanabe S, Enomoto N, <u>Koike K</u> , Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M.	Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-144	2010
<u>Koike K</u> , Moriya K, Matsuura Y.	Animal models for hepatitis C and related liver disease.	Hepatol Res	40	69-82	2010

Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, <u>Koike K.</u>	Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients.	Int J Cancer	129	2226-2235	2011
Inoue H, Yamazaki S, Shimizu M, Uozaki H, Goto T, Ohnishi S, <u>Koike K.</u>	Liver injury induced by the Japanese herbal drug kamishoyosan.	Gastroenterol Hepatol (NY)	7(10)	692-695	2011
Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, <u>Koike K.</u> , Omata M.	Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation.	Hepatol Int	5(3)	767-773	2011
Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, <u>Koike K.</u> , Moriishi K, Matsuura Y.	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus.	J Virol	85	13185-13194	2011
Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, <u>Koike K.</u>	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.	J Hepatol	55(6)	1400-1408	2011
Ishizaka N, Hongo M, Sakamoto A, Saito K, Furuta K, <u>Koike K.</u>	Liver lipid content is reduced in rat given 7-day administration of angiotensin II.	J Renin Angiotensin Aldosterone Syst	12(4)	462-468	2011

Bertot LC, Sato M, Tateishi R, Yoshida H, <u>Koike K.</u>	Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review.	Eur Radiol	21 (12)	462-468	2011
Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, <u>Koike K, Kokudo N.</u>	Diagnostic accuracy of $\alpha$ -fetoprotein and des- $\gamma$ -carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates.	Hepatol Res	41 (12)	1199-1207	2011
Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, <u>Koike K.</u>	Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species.	Oncology	Suppl 1	11-17	2011
Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, <u>Koike K, Yatomi Y.</u>	Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.	Cancer Epidemiol Biomarkers Prev	20 (10)	2204-2211	2011
Watanabe S, Enomoto N, <u>Koike K,</u> Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M ;PERFECT Study Group	Cancer preventive effect of pegylated interferon $\alpha$ -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41 (10)	955-964	2011
Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata	Receptor for activated protein kinase C: requirement for efficient microRNA function and reduced expression in hepatocellular	PLoS One	6(9)	e24359	2011

M, <u>Koike K.</u>	Carcinoma.				
Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, <u>Koike K.</u>	Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors.	Cancer	117 (19)	4475-4483	2011
Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, <u>Koike K.</u>	MicroRNA-22 and microRNA-140 suppress NF- $\kappa$ B activity by regulating the expression of NF- $\kappa$ B coactivators.	Biochem Biophys Res Commun	411 (4)	826-831	2011
Nakagawa H, Hirata Y, Takeda K, Hayakawa Y, Sato T, Kinoshita H, Sakamoto K, Nakata W, Hikiba Y, Omata M, Yoshida H, <u>Koike K.</u> , Ichijo H, Maeda S.	Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated MAPK.	Hepatology	54(1)	185-195	2011
Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, <u>Koike K.</u>	MicroRNA122 is a key regulator of $\alpha$ -fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma.	Nat Commun	2	338	2011
Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, <u>Koike K.</u>	Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a Single Center.	Transplantation	91 (11)	1261-1264	2011
Koshiyama A, Ichibangase T, Moriya K, <u>Koike K.</u> , Yazawa I, Imai K.	Liquid chromatographic separation of proteins derivatized with a fluorogenic reagent at	J Chromatogr A	1218 (22)	3447-3452	2011



	cysteiny residues on a non-porous column for differential proteomics analysis.				
Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otuska M, Tateishi R, Omata M, Nakagawa H, <u>Koike K</u> , Kamatani N, Kubo M, Nakamura Y, Matsuda K.	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.	Nat Genet	43(5)	455-458	2011
Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, <u>Koike K</u> , Yatomi Y.	Autotaxin as a novel serum marker of liver fibrosis.	Clin Chim Acta	412 (13-14)	1201-1206	2011
Kershenovich K, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, <u>Koike K</u> , Han K-H, Wallace CM, Zeuzem S, Negro F.	The global health burden of hepatitis C virus infection.	Liver Int	31 (S2)	4-17	2011
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, Amarapurkar D, Chen C-H, Dou X, El Khayat H, elShazly M, Esmat G, Guan R, Han K-H, <u>Koike K</u> , Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A,	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.	Liver Int	31 (S2)	61-80	2011

Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F.					
Yasui K, Hashimoto E, Komorizono Y, <u>Koike K</u> , Arie S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan.	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.	Clin Gastroenterol Hepatol	9(5)	428-433	2011
<u>Koike K</u> , Miyoshi H, Yotsyanagi H, Moriya K.	Effect of treatment with polyunsaturated fatty acids on HCV-or diet-induced fatty liver.	J Hepatol	54	1325-1326	2011
Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, <u>Koike K</u> .	Utility of contrast enhanced ultrasonography with sonazoid in radiofrequency ablation for hepatocellular carcinoma.	J Gastroenterol Hepatol	26(4)	759-764	2011
Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T, Miyamura T, Matsuura Y, Yotsyanagi H, <u>Koike K</u> .	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein.	J Hepatol.	54 (3)	432-438	2011
Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H,	Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for	Liver Int	31	197-205	2011

Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, <u>Koike K.</u>	hepatocellular carcinoma: impact on patient's prognosis.				
Yoshimi A, Yamamoto G, Goto T, <u>Koike K.</u> , Kurokawa M.	Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease.	Ann Hematol		2012 Feb 9. [Epub ahead of print]	
Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, <u>Koike K.</u>	Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.	J Gastroenterol		2011 Dec 27. [Epub ahead of print]	
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, <u>Koike K.</u>	Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.	Am J Gastroenterol		2011 Dec 13. doi: 10.1038/ajg.2011.425. [Epub ahead of print]	
Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, <u>Koike K.</u>	Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial.	Hepatol Int		2011 Aug 31. [Epub ahead of print]	
Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, <u>Koike K.</u>	Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.	J Gastroenterol.		2011 Sep 21. [Epub ahead of print]	
Takata A, Otsuka M, Kogiso T, Kojima K,	Direct differentiation of hepatic cells from human induced	Hepatol Int		2011 Feb 6. [Epub ahead of	

Yoshikawa T, Tateishi R, Kato N, Shiina S, Yoshida H, Omata M, <u>Koike</u> <u>K.</u>	pluripotent stem cells using a limited number of cytokines.			print]	
---	---	--	--	--------	--

#### IV. 研究成果の刊行物・別刷

# The Hepatitis C Virus Core Protein Contains a BH3 Domain That Regulates Apoptosis through Specific Interaction with Human Mcl-1<sup>∇†</sup>

Nur Khairiah Mohd-Ismail,<sup>1,2</sup> Lin Deng,<sup>3</sup> Sunil Kumar Sukumaran,<sup>4</sup> Victor C. Yu,<sup>4,5</sup>  
Hak Hotta,<sup>3</sup> and Yee-Joo Tan<sup>1\*</sup>

*Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Singapore<sup>1</sup>; NUS Graduate School for Integrative Sciences and Engineering, Singapore<sup>2</sup>; Division of Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan<sup>3</sup>; Mechanisms of Apoptosis in Mammalian Cell Group, Institute of Molecular and Cell Biology, Singapore<sup>4</sup>; and Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore<sup>5</sup>*

Received 11 March 2009/Accepted 8 July 2009

**The hepatitis C virus (HCV) core protein is known to modulate apoptosis and contribute to viral replication and pathogenesis. In this study, we have identified a Bcl-2 homology 3 (BH3) domain in the core protein that is essential for its proapoptotic property. Coimmunoprecipitation experiments showed that the core protein interacts specifically with the human myeloid cell factor 1 (Mcl-1), a prosurvival member of the Bcl-2 family, but not with other prosurvival members (Bcl-X<sub>L</sub> and Bcl-w). Moreover, the overexpression of Mcl-1 protects against core-induced apoptosis. By using peptide mimetics, core was found to release cytochrome *c* from isolated mitochondria when complemented with Bad. Thus, core is a bona fide BH3-only protein having properties similar to those of Noxa, a BH3-only member of the Bcl-2 family that binds preferentially to Mcl-1. There are three critical hydrophobic residues in the BH3 domain of the core protein, and they are essential for the proapoptotic property of the core protein. Furthermore, the genotype 1b core protein is more effective than the genotype 2a core protein in inducing apoptosis due to a single-amino-acid difference at one of these hydrophobic residues (residue 119). Replacing this residue in the J6/JFH-1 infectious clone (genotype 2a) with the corresponding amino acid in the genotype 1b core protein produced a mutant virus, J6/JFH-1(V119L), which induced significantly higher levels of apoptosis in the infected cells than the parental J6/JFH-1 virus. Furthermore, the core protein of J6/JFH-1(V119L), but not that of J6/JFH-1, interacted with Mcl-1 in virus-infected cells. Taken together, the core protein is a novel BH3-only viral homologue that contributes to the induction of apoptosis during HCV infection.**

Hepatitis C virus (HCV), a positive-stranded RNA virus of the family *Flaviviridae*, is the major cause of non-A, non-B hepatitis worldwide. The HCV genome encodes a precursor polyprotein of ~3,000 amino acids (aa) that is processed co-translationally and posttranslationally to give rise to viral structural and nonstructural proteins (2). The core protein is encoded by the N-terminal portion of the HCV precursor polyprotein and cleaved from the polyprotein by cellular signal peptidase to give the immature form of the core protein (aa 1 to 191). This then is further cleaved by membrane-associated signal peptide peptidase to give the mature core protein, whose C terminus is not precisely known but lies between residues 170 and 179 (see reviews in references 33, 42, and 52). The mature core protein is thought to constitute the HCV capsid and is the predominant form detected in virus particles purified from the sera of patients with chronic HCV infection (42, 74). A recent paper also reported that the maturation of the

core protein is required for the production of HCV using the JFH-1 infectious clone (65).

Besides its role in the encapsidation of viral RNA, the core protein has been found to interfere with many cellular pathways, including cell signaling, transcriptional activation, lipid metabolism, carcinogenesis, and apoptosis (see reviews in references 33, 42, and 52). As the regulation of apoptosis during viral infection is an important determinant in the struggle between virus and host for survival, many viruses encode viral proteins that can regulate apoptosis in the infected host cells and manipulate this process to their advantage. In the case of HCV, the mechanisms by which the virus maintains viral persistence and promotes hepatocellular carcinoma are not well understood, but several HCV proteins have the ability to modulate apoptosis (see recent reviews in references 20 and 28). In particular, the core protein has been shown to modulate apoptosis, and it seems that the core protein can inhibit as well as promote apoptosis, depending on the death stimuli and types of cells used (3, 9, 13, 25, 36, 40, 49, 53, 54, 57, 60, 76).

In this study, we characterized one of the mechanisms by which the mature form of the core protein from a genotype 1b strain induces apoptosis in Huh7 cells. Following the experimental designs used in previous studies (29, 38, 40, 55, 72), the mature form of the core protein is assumed to be constituted by residues 1 to 173 of the HCV precursor polyprotein, and

\* Corresponding author. Mailing address: Cancer and Developmental Cell Biology Division, Institute of Molecular and Cell Biology, 61 Biopolis Drive, A\*STAR (Agency for Science, Technology and Research), Biopolis, Singapore 136873, Singapore. Phone: 65-65869625. Fax: 65-67791117. E-mail: mcbtanyj@imcb.a-star.edu.sg.

† Supplemental material for this article may be found at <http://jvi.asm.org/>.

∇ Published ahead of print on 15 July 2009.

this shall be referred to as the core protein in this study. Here, we demonstrate that the core protein contains a functional Bcl-2 homology 3 (BH3) domain that is essential for its proapoptotic property and ability to interact with human myeloid cell factor 1 (Mcl-1), a prosurvival member of the Bcl-2 family (31). Detailed molecular analysis and infection studies using the J6/JFH-1 infectious clone showed that the core protein is a bona fide BH3-only protein that contributes to the induction of apoptosis during HCV infection by mimicking Noxa and interfering with the prosurvival function of Mcl-1.

#### MATERIALS AND METHODS

**Construction of plasmids.** Expression plasmids for the wild-type core protein and mutants were generated by PCR using Titanium *Taq* DNA polymerase (Clontech Laboratories Inc., Palo Alto, CA). Two plasmids containing full-length HCV genomes were used as templates. The first one is a 1b strain cloned in Singapore (59), and the second is the JFH-1 clone, which is a 2a strain (68). All sequences were confirmed by sequencing performed by the core facilities at the Institute of Molecular and Cell Biology, Singapore. The pXJ40flag vector is used so that a flag epitope is fused to the N terminus of the core protein, and this allows the comparison of protein expression levels with an anti-flag antibody.

**Transient transfections, CaspACE fluorometric assay, and Western blot analysis.** Transient transfections of Huh7 cells were performed using Lipofectamine reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Approximately 16 h after transfection, the activation of caspase-3 was quantified by using a CaspACE fluorometric assay system from Promega Corporation (Madison, WI) as previously described (63).

Western blot analysis was performed as previously described (64). The primary antibodies (anti-myc monoclonal and anti-myc and anti-Mcl-1 polyclonal [Santa Cruz Biotechnology, Santa Cruz, CA], anti-Mcl-1 monoclonal [Calbiochem, La Jolla, CA], anti-actin monoclonal, anti-Hsp-60 monoclonal, anti-flag monoclonal and polyclonal [Sigma, St. Louis, MO], anti-poly[ADP-ribose] polymerase [PARP] polyclonal [Cell Signaling Technology Inc., Beverly, MA], anti-cytochrome *c* monoclonal [BD PharMingen, BD Biosciences, San Jose, CA], and anti-Noxa [Imgenex, San Diego, CA]) were purchased. Anti-core protein monoclonal antibody (clone 2H9; a kind gift from T. Wakita, Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan) was used to detect the core protein of HCV (68).

**Coimmunoprecipitation experiments.** For the coimmunoprecipitation experiments, each 6-cm dish of cells was resuspended in 200  $\mu$ l of immunoprecipitation (IP) buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholic acid, 0.005% sodium dodecyl sulfate [SDS], and 1 mM phenylmethylsulfonyl fluoride) and subjected to freeze-thawing six times. Anti-flag monoclonal antibody conjugated to Sepharose beads (Sigma) were added to 150  $\mu$ l of the lysates, and the mixture was subjected to end-over-end mixing at 4°C for 6 h. Beads were washed four times with cold IP buffer, and then 15  $\mu$ l of Laemmli's SDS buffer was added and the samples were boiled at 100°C for 5 min to release the immunocomplexes. Samples were separated by SDS-polyacrylamide gel electrophoresis and subjected to Western blot analysis.

Alternatively, rabbit anti-Mcl-1 polyclonal antibody was used to immunoprecipitate endogenous Mcl-1 protein. In this case, 7  $\mu$ g of antibody (either anti-Mcl-1 or anti-hemagglutinin [HA] polyclonal antibody [Santa Cruz Biotechnology]) was added to the lysates obtained from two dishes of cells and allowed to mix for 1 h at room temperature. Protein A agarose beads (Roche, Indianapolis, IN) were added, and the mixture was subjected to end-over-end mixing at 4°C overnight. The coimmunoprecipitated proteins then were detected as described above.

**Quantification of autoradiographs.** An imaging densitometer (Bio-Rad, Hercules, CA) was used for the quantification of the intensities of specific bands on autoradiographs.

**In vitro cytochrome *c* release assay.** For the in vitro cytochrome *c* release assays, mitochondria were isolated from 293T cells as previously described (22). Briefly, 293T cells were suspended in isolation buffer (320 mM sucrose, 1 mM EDTA, 50 mM HEPES [pH 7.5]) and disrupted by 25 expulsions through a 27-gauge needle. The disrupted cells were spun at 1,000  $\times$  *g* for 10 min to remove cell debris and nuclei. The supernatant was centrifuged at 7,000  $\times$  *g* for 10 min, and the pellet was retained as the heavy membrane fraction containing the mitochondria. The mitochondrion-containing pellets then were resuspended in assay buffer (250 mM sucrose, 2 mM  $\text{KH}_2\text{PO}_4$ , 5 mM sodium succinate, 25 mM EGTA, and 10 mM HEPES [pH 7.5]) at 0.5 mg/ml. Equal amounts of mito-

chondria were treated with the indicated peptides for 30 min at room temperature, followed by centrifugation. Both the supernatant and pellet then were subjected to SDS-polyacrylamide gel electrophoresis, followed by Western blot analysis to determine the amount of cytochrome *c* released from the mitochondria. Hsp-60 was used as a loading control for the pellet.

**Synthesis of peptides.** A peptide that corresponds to residues 118 to 149 of the genotype 1b core protein (NLGKVIDTLTCGFADLMGYIPLVGAPLGG AAR) was synthesized and purified to 95% purity (Sigma Genosys, Japan). Peptides containing the BH3 domain of Bad (NLWAAQRYGRELRRMSDEF VDSFKK) or Noxa (VPADLKDECAQLRRIGDKVNLKQKL) also were synthesized and purified to 95% purity (Mimotopes, Clayton, Victoria, Australia).

**Generation of recombinant HCV.** The pFL-J6/JFH-1 plasmid encoding the entire viral genome of a chimeric strain of HCV genotype 2a, J6/JFH-1 (37), was kindly provided by C. M. Rice, Center for the Study of Hepatitis C, The Rockefeller University. To generate mutant virus possessing a core protein mutation, a nucleotide substitution was introduced into pFL-J6/JFH-1 by site-directed mutagenesis using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). All PCR-amplified DNA fragments were verified extensively using an ABI PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, CA). Each of the plasmids was linearized by *Xba*I digestion and in vitro transcribed by using T7 RiboMAX (Promega) to generate the full-length viral genomic RNA. The in vitro-transcribed RNA (10  $\mu$ g) was transfected into Huh7.5 cells by means of electroporation (975  $\mu$ F, 270 V) using a Gene Pulser (Bio-Rad). The cells then were cultured in complete medium, and the supernatant was propagated as a virus stock. Culture supernatants of uninfected cells served as a control (mock preparation). Virus infectivity was measured by indirect immunofluorescence as previously described (17) and expressed as cell-infecting units (CIU) per milliliter.

**Proliferation, caspase-3, and DNA fragmentation assays.** Huh7.5 cells were seeded in 96-well plates at a density of  $1.0 \times 10^4$  cells per well and cultured overnight. The cells then were infected with recombinant HCV at a multiplicity of infection of 0.1 CIU/cell or with a mock preparation. At different time points postinfection (p.i.), cell viabilities were determined by WST-1 proliferation assays (Roche, Mannheim, Germany) as described previously (17, 48).

Caspase-3 and DNA fragmentation assays also were performed on the infected cells as previously described (17).

**HCV RNA quantitation.** To measure intracellular HCV RNA replication levels, total RNA was extracted from the cells using an RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed using a QuantiTect reverse transcription kit (Qiagen) with random primers and was subjected to quantitative real-time PCR analysis using SYBR premix Ex *Taq* (Takara Bio, Kyoto, Japan) in a MicroAmp 96-well reaction plate and an ABI PRISM 7000 (Applied Biosystems, Foster, CA). The primers used to amplify an NS5A region of the HCV genome were 5'-AGACGTATTGAGGTCCATGC-3' (sense) and 5'-CCGCAGCGACGGTG CTGATAG-3' (antisense). As an internal control, human glyceraldehyde-3-phosphate dehydrogenase expression levels were measured using primers 5'-GCCATCAATGACCCCTTCATT-3' (sense) and 5'-TCTCGCTCCTGGAAGA TGG-3' (antisense).

**Statistical analysis.** Either the two-tailed Student's *t* test or one-way analysis of variance (using SPSS version 16.0) was applied to evaluate the statistical significance of differences measured from the data sets.  $P < 0.05$  was considered statistically significant.

## RESULTS

**A BH3-like domain is present in the core protein.** The family of Bcl-2 proteins constitutes one of the biologically important gene products in the regulation of apoptosis (see recent reviews in references 1, 16, 67, and 75). The Bcl-2 proteins may be classified broadly into three classes: prosurvival members containing multiple Bcl-2 homology domains, proapoptotic members containing multiple Bcl-2 homology domains, and proapoptotic members containing the BH3 domain only. The examination of the amino acid sequence of the core protein revealed that there is a BH3-like domain near the C terminus. An alignment of this domain with BH3 domains of the Bcl-2 family of proteins is shown in Fig. 1A. The BH3-like domain of the core protein contains L (residue 119) and D (residue 124)




FIG. 1. Identification of a BH3-like domain in the core protein. (A) Alignment of the BH3 domain of the genotype 1b core protein with the BH3 domains of members of the Bcl-2 family. Numbers in parentheses represent the positions of amino acid residues of the respective proteins. The four hydrophobic amino acids that make critical contacts with residues in the BH3 recognition grooves present on the surfaces of the prosurvival Bcl-2 family proteins are indicated as h1 to h4. (B) Alignment of the core protein (residues 109 to 132) of different genotypes. The consensus sequences for these genotypes were obtained from <http://hcv.lanl.gov/content/hcv-index>. The highly conserved L and D residues, at positions 119 and 124 of the genotype 1b core protein, respectively, in BH3 domains are boxed.

separated by four residues, as in other known BH3 domains. This domain is highly conserved among the major HCV genotypes, with the exception of genotypes 2a and 6k, which have V and M residues at position 119, respectively (Fig. 1B).

**The BH3 domain of the core protein is essential for the induction of apoptosis and its interaction with human Mcl-1.** The overexpression of the core protein (with a flag epitope at the N terminus) in Huh7 cells, via the transient transfection of a cDNA expression plasmid containing the genotype 1b core protein gene, induced significant levels of apoptosis as determined by the activation of caspase-3, which is a hallmark of apoptosis (Fig. 2A). The deletion of the BH3 domain in the core protein (designated coreΔ115-128aa) abolished its pro-apoptotic property, indicating that this domain is essential for the induction of apoptosis. Consistently, the cleavage of en-

dogenous PARP, a substrate of activated caspase-3, was clearly observed in Huh7 cells expressing the wild-type core protein but not in those expressing coreΔ115-128aa (Fig. 2B).

To understand how the core protein modulates the function of the Bcl-2 family of proteins, coimmunoprecipitation experiments were performed to determine if the core protein can interact with representative prosurvival members of the Bcl-2 family. As shown in the top panel of Fig. 3A, Mcl-1 was specifically coimmunoprecipitated by the core protein (lane 8) but not by an irrelevant protein, glutathione S-transferase (GST) (lane 7). The BH3 domain of the core protein is essential for its interaction with Mcl-1, as coreΔ115-128aa failed to coimmunoprecipitate Mcl-1 (lane 9). These results indicate that the core protein induces apoptosis by interfering directly with the prosurvival function of Mcl-1. In contrast, no significant inter-






FIG. 2. Induction of apoptosis by the overexpression of the core protein in Huh7 cells. (A) A CaspACE fluorometric assay system from Promega Corporation (Madison, WI) was used to measure the activation of caspase-3, which is a hallmark of apoptosis, in Huh7 cells that were transfected with vector only, a classical apoptosis inducer (Bax), the wild-type core protein, and a core protein mutant lacking the putative BH3 domain (core $\Delta$ 115-128aa). All experiments were performed in triplicate, and the average values with standard deviations are plotted. (B) Western blot analysis also was performed to determine the cleavage of endogenous PARP, which is a substrate of activated caspase-3, from 116 to 83 kDa (top). Similarly, the expression levels of the different proteins were determined using anti-flag antibody (middle). The amounts of total cell lysates loaded were verified by measuring the levels of endogenous actin (bottom).

action was observed between the core protein and two other prosurvival proteins, Bcl-X<sub>L</sub> and Bcl-w (lanes 1 to 6).

The interaction between the core protein and endogenous Mcl-1 was determined by overexpressing the core protein in Huh7 cells. As shown in Fig. 3B, the core protein was coimmunoprecipitated with endogenous Mcl-1 (lane 3). On the other hand, the core protein was not coimmunoprecipitated when an irrelevant antibody (anti-HA) (lane 4) was used for IP. Consistently with the results in Fig. 3A, only a small amount of core $\Delta$ 115-128aa was coimmunoprecipitated with endogenous Mcl-1 (lane 5). To estimate the degree of reduction in the binding of core $\Delta$ 115-128aa to endogenous Mcl-1, an

imaging densitometer was used to quantify the intensities of specific bands on the autoradiographs obtained in three independent coimmunoprecipitation experiments (see Fig. S1 in the supplemental material). The ratios of signals for the expression of flag-tagged core protein, endogenous Mcl-1, and actin (internal control) all are close to 1 (0.94 to 1.14), indicating that the expression levels of these proteins in the two sets of cells (either transfected with cDNA construct for expressing flag-core or flag-core $\Delta$ 115-128aa) were similar. From the three independent experiments, the average amount of core $\Delta$ 115-128aa coimmunoprecipitated specifically by the Mcl-1 antibody is 14.2% ( $\pm$  10.7%) of the amount of wild-type core protein coimmunoprecipitated. This implies that the deletion of the BH3 domain does not completely abolish the interaction between the core protein and endogenous Mcl-1 but reduces the interaction greatly.

**Overexpression of Mcl-1 or Bcl-X<sub>L</sub> prevents core protein-induced apoptosis.** To examine the protective effects of the prosurvival Bcl-2 proteins in Huh7 cells, transfections were performed with plasmids expressing myc-tagged Bcl-2, Bcl-X<sub>L</sub>, Bcl-w, or Mcl-1 (Fig. 4A and B). Consistent with studies of other cell lines (12, 66), the transient high-level expression of Bcl-2 also caused apoptosis in Huh7 cells (lane 1). Interestingly, the overexpression of Bcl-w also induced a significant level of apoptosis in Huh7 cells (lane 3), and this phenomenon has not been reported previously. Cells overexpressing Bcl-X<sub>L</sub>, but not Mcl-1, also had a slightly higher level of apoptosis than that of the vector control cells (lanes 2 and 4).

Huh7 cells were cotransfected with plasmids for expressing myc-Mcl-1 and flag-core or myc-Bcl-X<sub>L</sub> and flag-core. As shown in Fig. 4C and D, the level of apoptosis was significantly reduced in cells expressing both Mcl-1 and the core protein (lane 3) compared to those expressing the core protein only (lane 2). When the same experiment was repeated using Bcl-X<sub>L</sub>, the level of apoptosis was reduced to a lesser extent (lane 5). However, this may be due to the low level of apoptosis induced by the overexpression of Bcl-X<sub>L</sub> (lane 6). The level of the core protein expressed in the presence of Bcl-X<sub>L</sub> also was decreased greatly, but the smaller amount of the core protein expressed still induced a high level of apoptosis (lane 5). However, when a broad caspase inhibitor (z-VAD-fmk) was used, the core protein level in cells coexpressing Bcl-X<sub>L</sub> increased (see Fig. S2 in the supplemental material), indicating that the transfection efficiencies were similar in the different samples. To resolve this uncertainty, the experiment was repeated with a smaller amount of Bcl-X<sub>L</sub> plasmid (0.5  $\mu$ g). Under this condition, the overexpression of Bcl-X<sub>L</sub> did not induce apoptosis (lane 8), and the level of apoptosis also was reduced in cells expressing both Bcl-X<sub>L</sub> and the core protein (lane 7) compared to those expressing the core protein only (lane 2). Thus, the results show that the overexpression of either Mcl-1 or Bcl-X<sub>L</sub> protects against core protein-induced apoptosis.

**Bad enhances the ability of the core protein to release cytochrome c from isolated mitochondria.** The ability of a core protein peptide, which contains residues 118 to 149 of the genotype 1b core protein, to release cytochrome c from the mitochondria was tested using 293T cells instead of Huh7 cells, as the method for the isolation of mitochondria from 293T cells is well established. The core protein induced apoptosis in 293T cells in the same manner as that in Huh7 cells (see Fig.




FIG. 3. Interaction of the core protein with prosurvival members of the Bcl-2 family determined by coimmunoprecipitation experiments. (A) Huh7 cells were transfected with cDNA constructs for expressing flag-GST (negative control), flag-core, or flag-coreΔ115-128aa, and myc-tagged prosurvival members of the Bcl-2 family (myc-Bcl-X<sub>L</sub> [lanes 1 to 3], myc-Bcl-w [lanes 4 to 6], and myc-Mcl-1 [lanes 7 to 9]). The cells were harvested at ~16 h posttransfection, lysed, and subjected to IP with anti-flag monoclonal antibody conjugated to Sepharose beads. The amount of myc-tagged proteins that coimmunoprecipitated (IP) with the flag-tagged proteins was determined by Western blot analysis (WB) with an anti-myc rabbit polyclonal antibody (top). The amounts of myc-tagged and flag-tagged proteins in the lysates before IP were determined by subjecting aliquots of the lysates to Western blot analysis (middle). The protein marked with an asterisk represents the heavy chain of the antibody used for IP (top), and the amounts of total cell lysates loaded were verified by measuring the levels of endogenous actin (bottom). (B) Huh7 cells were transfected with cDNA constructs for expressing flag-core or flag-coreΔ115-128aa. IP then was performed using anti-Mcl-1 or anti-HA rabbit polyclonal antibodies and protein A agarose beads. The amounts of flag-tagged core protein in the lysates before IP (lanes 1 and 2) or coimmunoprecipitated (lanes 3 to 6) were determined by Western blot analysis with an anti-flag monoclonal antibody (top). Similarly, the amounts of endogenous Mcl-1 in these samples were detected using an anti-Mcl-1 monoclonal antibody (middle). The protein marked with an asterisk represents the heavy chain of the antibody used for IP (top), and the amounts of total cell lysates loaded were verified by measuring the levels of endogenous actin (bottom).

S3 in the supplemental material). As shown in Fig. 5A, both the Bad and core protein peptides were inefficient in inducing the release of cytochrome *c*, as only a small amount of cytochrome *c* was detected in the supernatant from the treated mitochondria when 200 μM of either peptide was used. However, when Bad and core protein peptides were used in combination, the release of cytochrome *c* was observed at the much lower concentration of 50 μM (consisting of 25 μM Bad peptide and 25 μM core protein peptide). Furthermore, the release of cytochrome *c* increased in a dose-dependent manner. The amount of cytochrome *c* left in the treated mitochondria (i.e., pellet) decreased correspondingly, while the amount of control protein, Hsp-60, was not affected.

The same experiment was repeated using the Noxa peptide (Fig. 5B). Consistently with a previous study (11), the Noxa peptide alone was inefficient in inducing the release of cytochrome *c*, but when it was combined with the Bad peptide, the release was significantly enhanced. The peptide(s) dosage required was similar to the amount required for the core protein and Bad, indicating that the complementation between the

core protein and Bad is similar to the complementation between Noxa and Bad. In addition, complementation between the core protein and Bad also was observed when they were coexpressed in Huh7 cells (see Fig. S4 in the supplemental material).

**The three hydrophobic residues in the BH3 domain of the core protein are important for apoptosis induction.** Site-directed mutagenesis and structural studies of the interactions between the prosurvival Bcl-2 proteins and BH3 domains have revealed the mechanism by which BH3 domains are bound to the hydrophobic grooves present on the surfaces of the prosurvival Bcl-2 proteins (see reviews in references 50 and 69). In particular, the BH3 domain usually contains four hydrophobic residues (h1, h2, h3, and h4) (Fig. 1A) that make contacts critical for the stability of the complex. Interestingly, the core protein contains hydrophobic residues at the h2, h3, and h4 positions (Fig. 1A). An alanine substitution experiment was performed to determine if these residues are essential for the proapoptotic property of the core protein (Fig. 6A and B). The results showed that replacement of either L119, V122, or L126




FIG. 4. Effects of Mcl-1 and Bcl-X<sub>L</sub> overexpression on the proapoptotic property of the core protein. (A) A CaspACE fluorometric assay system from Promega Corporation (Madison, WI) was used to measure the activation of caspase-3 in Huh7 cells that were transfected with Bcl-2, Bcl-X<sub>L</sub>, Bcl-w, Mcl-1, or vector only. All experiments were performed in triplicate, and the average values with standard deviations are plotted. (B) Western blot analysis also was performed to determine the cleavage of endogenous PARP (top) and expression levels of the myc-tagged prosurvival members of the Bcl-2 family (middle). The amounts of total cell lysates loaded were verified by measuring the levels of endogenous actin (bottom). (C) A CaspACE fluorometric assay system from Promega Corporation (Madison, WI) was used to measure the activation of caspase-3 in Huh7 cells that were singly transfected with vector, the wild-type core protein, Mcl-1, or Bcl-X<sub>L</sub>, or that were cotransfected with wild-type core protein and Mcl-1 or Bcl-X<sub>L</sub>. The amounts of flag-core and myc-Mcl-1 or myc-Bcl-X<sub>L</sub> DNAs used in each of the transfections are indicated in micrograms. In each transfection, the total amount of DNA was normalized to 3  $\mu$ g with the addition of empty vector if necessary. All experiments were performed in triplicate, and the average values with standard deviations are plotted. (D) Western blot analysis also was performed to determine the cleavage of endogenous PARP (top) and expression levels of myc-tagged Mcl-1 and Bcl-X<sub>L</sub> and flag-tagged core protein (middle). The amounts of total cell lysates loaded were verified by measuring the levels of endogenous actin (bottom).

with A completely abolishes the proapoptotic property of the core protein. On the other hand, the replacement of the highly conserved D124 residue with A seems to increase the proapoptotic property of the core protein slightly. The levels of activated caspase-3 induced by the wild-type core protein and the D124A substitution mutant in six independent experiments were compared using the two-tailed Student's *t* test, and the difference was found to be statistically significant (Fig. 6C). This phenomenon has not been reported for other BH3-only proteins, but there are a few known functional BH3 domains that do not contain D at this position (54, 55).

Furthermore, coimmunoprecipitation experiments showed that the L119A, V122A, and L126A substitution mutants have reduced binding to Mcl-1 (Fig. 7A). Similar results were obtained in four independent experiments, and the percentages of binding compared to that of the wild-type core protein were estimated by using an imaging densitometer to measure the

intensity of the core protein signals after coimmunoprecipitation. For each experiment, three different autoradiographs (with different exposure times) were used, and the average values are shown in Table S1 in the supplemental material. The average percentages in binding of Mcl-1 to the L119A, V122A, and L126A mutants are 33, 62, and 9% of the binding to the wild-type core protein, respectively. For all three mutants, the reduced interactions with Mcl-1 compared to those of the wild-type core protein are statistically significant (see Table S1 in the supplemental material). As the D124A substitution mutant induced a slightly higher level of apoptosis than the wild-type core protein (Fig. 6), a coimmunoprecipitation experiment also was performed to determine if this mutant can bind Mcl-1. Two different amounts of flag-tagged plasmids (0.5 and 1.0  $\mu$ g) were used, and the results show that the D124A substitution mutant binds Mcl-1 to an extent similar to that of the wild-type core protein under both conditions (Fig. 7B).




FIG. 5. Release of cytochrome *c* from isolated mitochondria by a combination of the core-BH3 and Bad-BH3 peptides or Noxa-BH3 and Bad-BH3 peptides. (A) Mitochondria isolated from 293T cells were incubated with either Bad peptide, core protein peptide, or a combination of the two peptides in equimolar concentrations. The total amount of peptide used in each experiment is indicated. Following centrifugation, the supernatants and pellets were subjected to Western blot analysis with anti-cytochrome *c* (cyt *c*) or anti-Hsp-60 antibodies. (B) The same experiment was repeated with Noxa peptide or a combination of Noxa and Bad peptides in equimolar concentrations.

While the V122 and L126 residues, at the h3 and h4 positions, respectively, of the core protein are highly conserved in different genotypes of HCV, the core proteins from genotype 2a strains typically have V instead of L at the h2 position (Fig. 1B). Replacing the L119 of the genotype 1b core protein with V reduced the proapoptotic property of the core protein dramatically (Fig. 8). Interestingly, in all known BH3-only proteins, this position is usually an L residue that is essential for the proapoptotic properties of these proteins (Fig. 1A). The reverse experiment was performed by determining if the core protein of a genotype 2a strain (JFH-1 strain) can induce apoptosis. The overexpression of the genotype 2a core protein induced much less apoptosis than the genotype 1b core protein (Fig. 8). However, replacing the V119 of the genotype 2a core protein with L resulted in a significant increase in apoptosis induction, such that the level was similar to that induced by the genotype 1b core protein (Fig. 8).

**A single substitution from V to L at residue 119 in the core protein of the HCV J6/JFH-1 strain is associated with increased abilities to induce apoptosis.** The pFL-J6/JFH-1 plasmid encoding the entire viral genome of a chimeric strain of HCV genotype 2a (J6/JFH-1) can be used to generate infectious HCV (37). In the J6/JFH-1 clone, the core protein contains V at residue 119, just like the JFH-1 clone. A mutant virus, J6/JFH-1(V119L), was generated successfully by replacing the V119 residue with L. Parental J6/JFH-1 and mutant J6/JFH-1(V119L) viruses then were used to infect naïve Huh7.5 cells, and cell viabilities were measured at different time points after infection (Fig. 9A). From day 2 p.i., cells infected by either virus have lower viabilities than mock-infected cells, indicating that the viruses have induced cytopathic effects (CPE). This is consistent with recent observations by us and other researchers (17, 41). Results from days 6 and 8 p.i. show that the J6/JFH-1(V119L) virus induced higher levels of CPE and, therefore, lower levels of cell viability compared to those of the parental J6/JFH-1 virus (Fig. 9A), which is in

agreement with the overexpression studies shown in Fig. 8. The CPE is mediated primarily through apoptosis, as indicated by the activation of caspase-3 (Fig. 9B) and DNA fragmentation (Fig. 9C). The production of cell-free infectious virus particles by the J6/JFH-1(V119L) virus also was significantly higher than that produced by the parental J6/JFH-1 virus (Fig. 9D). On the other hand, there was no significant difference in the percentage of HCV-infected cells in the cultures (Fig. 9E) or HCV RNA replication in the cells between the two viruses (Fig. 9F). We next analyzed the possible interaction between endogenous Mcl-1 and the core proteins of either J6/JFH-1 or J6/JFH-1(V119L) in virus-infected cells. As shown in Fig. 9G, the core protein of J6/JFH-1(V119L) was coimmunoprecipitated with Mcl-1 (lane 6). On the other hand, the Mcl-1 interaction of the core protein of J6/JFH-1 was barely detected under the same experimental conditions (lane 4). These results collectively imply the possibility that the V119L mutation of the core protein promotes its interaction with Mcl-1 and is responsible for the increased ability of the virus to induce apoptosis, which favors a higher degree of infectious progeny virus release from the host cell at the late time points of infection compared to that of the parental J6/JFH-1 virus.

## DISCUSSION

Besides playing important roles in maintaining homeostasis in healthy cells through the regulation of apoptosis, members of the Bcl-2 family also are involved in viral infections. Indeed, several viruses have been shown to encode homologs of pro-survival Bcl-2 proteins, and these viral proteins act to inhibit apoptosis in infected cells and prevent the premature death of these cells (see reviews in references 14, 26, 51, and 70). Other viral proteins, which can be proapoptotic, prosurvival, or both, do not share any sequence homology with members of the Bcl-2 family but also can modulate apoptosis in the host cells